SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers

Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers


  • Org Study ID: STUDY00141546
  • Secondary ID:
  • NCT ID: NCT03413982
  • NCT Alias:
  • Sponsor: University of Kansas Medical Center - Other
  • Source: University of Kansas Medical Center

Brief Summary

The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. The registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are related to tumor development, recurrence and survival.

Overal Status Start Date Phase Study Type
Recruiting November 2, 2017 N/A Observational [Patient Registry]

Primary Outcomes:

Primary Outcome 1 - Measure: Blood, urine and tissue characteristics of bladder cancer patients

Primary Outcome 1 - Time Frame: 24 months

Condition:

  • Bladder Cancer

Eligibility

Criteria:
Inclusion Criteria:

- Patients who present to clinic with presumed bladder cancer or have a diagnosis of
bladder cancer are eligible to participate

- Patients can participate in any additional research studies during the patients'
participation within this protocol.

Exclusion Criteria:

- Patients who do not have presumed bladder cancer will not be eligible
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: John Taylor, MD

Role: Principal Investigator

Affiliation: University of Kansas Medical Center

Overall Contact

Name: Katie Glavin

Phone: 913-588-8721

Email: kglavin@kumc.edu

Location

Facility Status Contact
University of Kansas Medical Center
Kansas City, Kansas 66160
United States
Recruiting